Venus emedies Launched Tobracef

Today, Venus Remedies has announced that the company has successfully launched its fourth research product, a fixed dose combination of cephalosporin with aminoglycoside under the brand name Tobracef in domestic market for the first time golbally. The Drug Controller General of India has accorded its approval to Venus Remedies for launch of the fourth innovative product developed by Venus Research Centre, after completion of its multi-centered Phase III clinical trials and all related studies in March 2008.

Tobracef, is a god send for APE/Cystic Fibrosis patients being the only solution for the treatment of life threatening infections caused by P Aeruginosa / MRSA in these patients. The PSD division is targeting to fast penetrate the Rs 2 billion domestic market and is expected to build this brand as a segment leader within 2 years of its launch. There are 50 patent applications in process in 50 countries across the globe for this wonderful product and the company is in talks for out-licencing of this product in US and other regulated markets of the world.